Hyperlipidemia.
Over the past 20 years, a link between lipoprotein disorders and atherosclerosis, and its clinical manifestations of myocardial infarction, stroke, and sudden cardiac death, has been conclusively demonstrated. This article reviews lipoprotein metabolism, its pathophysiology, describes an approach for the management of patients with lipid disorders and discusses therapy using the ATP III guidelines.
Eaton
Charles B
CB
Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA. Charles_Eaton@mhri.org
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy / Q000503:physiopathology*; D015243:Cholesterol, VLDL; D018752:Diet, Fat-Restricted; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D017270:Lipoprotein(a); D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000379:methods*; D014280:Triglycerides
D000924:Anticholesteremic Agents; D015243:Cholesterol, VLDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D014280:Triglycerides